B Steffansen
Overview
Explore the profile of B Steffansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Franek F, Jarlfors A, Larsen F, Holm P, Steffansen B
Eur J Pharm Sci
. 2015 Jun;
77:303-13.
PMID: 26091569
Desvenlafaxine is a biopharmaceutics classification system (BCS) class 1 (high solubility, high permeability) and biopharmaceutical drug disposition classification system (BDDCS) class 3, (high solubility, poor metabolism; implying low permeability) compound....
2.
Nielsen C, Amstrup J, Nielsen R, Steffansen B, Frokjaer S, Brodin B
Acta Physiol Scand
. 2003 Jun;
178(2):139-48.
PMID: 12780388
Aims: Little is known about the physiological regulation of the human intestinal di/tri-peptide transporter, hPepT1. In the present study we evaluated the effects of epidermal growth factor (EGF) and insulin...
3.
Nielsen C, Andersen R, Brodin B, Frokjaer S, Taub M, Steffansen B
J Control Release
. 2001 Sep;
76(1-2):129-38.
PMID: 11532319
The human intestinal di/tri-peptide carrier, hPepT1, has been suggested as a drug delivery target via increasing the intestinal transport of low permeability compounds by designing peptidomimetic prodrugs. Model ester prodrugs...
4.
Friedrichsen G, Nielsen C, Steffansen B, Begtrup M
Eur J Pharm Sci
. 2001 Jul;
14(1):13-9.
PMID: 11457645
The human peptide transporter, hPepT1, situated in the small intestine, may be exploited to increase absorption of drugs or model drugs by attaching them to a dipeptide, which is recognised...
5.
Nielsen C, Amstrup J, Steffansen B, Frokjaer S, Brodin B
Am J Physiol Gastrointest Liver Physiol
. 2001 Jun;
281(1):G191-9.
PMID: 11408272
The human intestinal cell line Caco-2 was used as a model system to study the effects of epidermal growth factor (EGF) on peptide transport. EGF decreased apical-to-basolateral fluxes of [(14)C]glycylsarcosine...
6.
Nielsen C, Andersen R, Brodin B, Frokjaer S, Steffansen B
J Control Release
. 2001 May;
73(1):21-30.
PMID: 11337056
The human intestinal di/tri-peptide carrier, hPepT1, has been suggested as a target for increasing intestinal transport of low permeability compounds by creating prodrugs designed for the transporter. Model ester prodrugs...
7.
Lepist E, Kusk T, LARSEN D, Andersen D, Frokjaer S, Taub M, et al.
Eur J Pharm Sci
. 2000 Jul;
11(1):43-50.
PMID: 10913752
One approach to increase drug stability and to facilitate oral absorption of low bioavailability drugs may be to design oligopeptide ester prodrugs which are stable in the gastrointestinal tract, are...
8.
Gammelgaard B, Jensen K, Steffansen B
J Trace Elem Med Biol
. 1999 Aug;
13(1-2):82-8.
PMID: 10445223
The purpose of these studies was to compare the in vitro absorption of two inorganic chromium(III) compounds: chromium chloride and chromium nitrate, with organic chromium(III)-picolinate; and to investigate if any...
9.
Steffansen B, Lepist E, Taub M, Larsen B, Frokjaer S, Lennernas H
Eur J Pharm Sci
. 1999 Mar;
8(1):67-73.
PMID: 10072480
The model prodrug D-Asp(OBzl)-Ala has previously been shown to have affinity and to be transported by the oligopeptide transporter PepT1 expressed in Caco-2 cells. The main objective of the present...
10.
Chen M, Christensen S, Zhai L, Rasmussen M, Theander T, Frokjaer S, et al.
J Infect Dis
. 1997 Nov;
176(5):1327-33.
PMID: 9359735
Previous studies have shown that licochalcone A, an oxygenated chalcone, exhibits antileishmanial and antimalarial activities. The present study was designed to examine the antimalarial activity of an analog of licochalcone...